Compare Stocks → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CLRBOTCMKTS:CNTTFNASDAQ:CWBRNASDAQ:PPBT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLRBCellectar Biosciences$3.02-1.3%$3.63$1.33▼$4.45$97.43M0.921.65 million shs678,612 shsCNTTFCannTrust$9.60$4.35▼$11.97$1.01B4.52528,025 shs1.43 million shsCWBRCohBar$0.80$0.82$0.51▼$6.90$2.33M1.541,006 shs7 shsPPBTPurple Biotech$0.52$0.67$0.30▼$2.10$13.02M0.94131,313 shs1.66 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLRBCellectar Biosciences-1.31%-0.66%-21.56%-19.47%+106.71%CNTTFCannTrust0.00%0.00%0.00%0.00%0.00%CWBRCohBar0.00%-11.14%+5.21%+3.15%-54.29%PPBTPurple Biotech-0.96%+11.93%-17.19%-22.09%-73.94%“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars).MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLRBCellectar Biosciences2.2158 of 5 stars3.54.00.00.02.50.00.6CNTTFCannTrustN/AN/AN/AN/AN/AN/AN/AN/ACWBRCohBarN/AN/AN/AN/AN/AN/AN/AN/APPBTPurple Biotech1.3643 of 5 stars3.53.00.00.01.10.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLRBCellectar Biosciences3.00Buy$20.00562.25% UpsideCNTTFCannTrustN/AN/AN/AN/ACWBRCohBarN/AN/AN/AN/APPBTPurple Biotech3.00Buy$9.001,644.19% UpsideCurrent Analyst RatingsLatest PPBT, CNTTF, CWBR, and CLRB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2024CLRBCellectar BiosciencesRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $28.003/28/2024CLRBCellectar BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.00 ➝ $12.003/5/2024PPBTPurple BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/4/2024CLRBCellectar BiosciencesRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.002/27/2024PPBTPurple BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLRBCellectar BiosciencesN/AN/AN/AN/A($0.36) per shareN/ACNTTFCannTrust$15.96M0.00N/AN/AN/ANaNCWBRCohBarN/AN/AN/AN/A$5.27 per shareN/APPBTPurple BiotechN/AN/AN/AN/A$1.36 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLRBCellectar Biosciences-$37.98M-$3.10N/AN/AN/AN/A-3,821.29%-280.23%5/2/2024 (Estimated)CNTTFCannTrustN/A$0.07137.180.00N/AN/AN/AN/AN/ACWBRCohBar-$12.18M-$4.36N/A∞N/AN/AN/AN/A5/13/2024 (Estimated)PPBTPurple Biotech-$19.88M-$0.92N/AN/AN/AN/A-57.40%-49.02%5/21/2024 (Estimated)Latest PPBT, CNTTF, CWBR, and CLRB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023CLRBCellectar Biosciences-$0.59-$0.66-$0.07-$0.92N/AN/A3/5/2024Q4 2023PPBTPurple Biotech-$0.17-$0.32-$0.15-$0.45N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLRBCellectar BiosciencesN/AN/AN/AN/AN/ACNTTFCannTrustN/AN/AN/AN/AN/ACWBRCohBarN/AN/AN/AN/AN/APPBTPurple BiotechN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLRBCellectar BiosciencesN/A0.810.81CNTTFCannTrustN/AN/AN/ACWBRCohBarN/AN/AN/APPBTPurple BiotechN/A2.202.20OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLRBCellectar Biosciences16.41%CNTTFCannTrust0.08%CWBRCohBar2.47%PPBTPurple Biotech9.64%Insider OwnershipCompanyInsider OwnershipCLRBCellectar Biosciences4.60%CNTTFCannTrustN/ACWBRCohBar6.51%PPBTPurple Biotech2.98%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCLRBCellectar Biosciences2032.26 million30.78 millionOptionableCNTTFCannTrustN/A105.61 millionN/ANot OptionableCWBRCohBar92.91 million2.72 millionNot OptionablePPBTPurple Biotech2025.24 million24.49 millionOptionablePPBT, CNTTF, CWBR, and CLRB HeadlinesSourceHeadlinePurple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meetingglobenewswire.com - April 25 at 7:00 AMPurple Biotech (NASDAQ:PPBT) Trading Up 8.1%americanbankingnews.com - April 24 at 2:18 AMPurple Biotech Ltd (PPBT)investing.com - April 17 at 11:15 PMPurple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024finance.yahoo.com - March 28 at 11:13 AMPurple Biotech Ltd.: Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technologyfinanznachrichten.de - March 14 at 12:40 PMPurple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technologyglobenewswire.com - March 14 at 7:30 AMHere's Why Purple Biotech Ltd. Sponsored ADR (PPBT) Could be Great Choice for a Bottom Fisherzacks.com - March 13 at 10:56 AMPPBT Stock Earnings: Purple Biotech Meets EPS for Q4 2023investorplace.com - March 5 at 11:52 PMPurple Biotech Ltd.: Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Resultsfinanznachrichten.de - March 5 at 1:22 PMPurple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Resultsglobenewswire.com - March 5 at 7:55 AMPurple Biotech ADR (PPBT) Earnings Dates & Reportsinvesting.com - March 3 at 6:09 PMBuy Rating Justified by Promising Phase 1 Results of Purple Biotech’s NT219 in SCCHN Treatmentmarkets.businessinsider.com - February 27 at 10:57 PMPurple Biotech Ltd ADRmorningstar.com - February 27 at 5:56 PMPurple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024globenewswire.com - February 27 at 7:00 AMPurple Biotech Ltd. ADRwsj.com - February 22 at 2:20 PMPurple Biotech Ltd ADR PPBTmorningstar.com - February 15 at 12:30 AMPurple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trialfinance.yahoo.com - February 13 at 8:34 AMAnalysts Offer Insights on Healthcare Companies: Purple Biotech (PPBT) and Sanofi (OtherSNYNF)markets.businessinsider.com - February 1 at 5:47 PMPurple Biotech stock climbs 9% on Phase 2 study updatemsn.com - February 1 at 12:47 PMPurple Biotech Reaches Recommended Phase 2 Dose for NT219finance.yahoo.com - February 1 at 7:47 AMPurple Biotech Appoints Dr. Yael Margolin to its Board of Directorsfinance.yahoo.com - December 20 at 9:18 AMPurple Biotech Ltd.: Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trialfinanznachrichten.de - December 14 at 10:30 AMPurple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trialfinance.yahoo.com - December 14 at 10:30 AMEncouraging Early Data For Biotech's Cancer Therapiesinvestorideas.com - November 22 at 12:58 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCellectar BiosciencesNASDAQ:CLRBCellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.CannTrustOTCMKTS:CNTTFCannTrust Holdings Inc. produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company has a partnership with Gold Coast University Hospital. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.CohBarNASDAQ:CWBRCohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.Purple BiotechNASDAQ:PPBTPurple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company for the Phase 2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy; and Mor Research Applications. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.